Keytruda pembrolizumab: Additional Phase Ib data

Data from 550 patients with advanced NSCLC in the open-label, U.S. Phase Ib KEYNOTE-001 trial showed that Keytruda led to a median OS of 22.1 months in treatment-naive patients (n=101) and 10.6 months in

Read the full 346 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE